A provider-focused update on Tadalafil availability in 2026. Covers shortage status, prescribing implications, cost considerations, and tools for clinicians.
Tadalafil is one of the most commonly prescribed PDE5 inhibitors in the United States, with FDA-approved indications spanning erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). As patient demand for this medication continues to grow — driven in part by the expansion of telehealth prescribing — providers should stay informed about current availability, cost dynamics, and practical strategies for ensuring patient access.
This article provides a concise briefing on Tadalafil's supply status in 2026, prescribing considerations, and tools to help your patients find and afford their medication.
As of early 2026, Tadalafil is not listed on the FDA Drug Shortages database or the ASHP drug shortage list. There is no recognized national shortage.
Tadalafil has not experienced a significant nationwide shortage historically. Unlike medications such as Adderall or certain GLP-1 agonists, Tadalafil benefits from a robust generic market with multiple manufacturers. Supply has remained generally stable since generic entry following Cialis's patent expiration in 2018.
That said, providers should be aware that localized stock-outs do occur. Patients may report difficulty filling prescriptions at specific pharmacies, particularly for less common doses (2.5 mg, 10 mg) or in areas with high telehealth-driven demand.
Several factors are worth considering when prescribing Tadalafil in the current landscape:
The most significant access barrier for Tadalafil is not supply — it's insurance coverage. The majority of commercial insurance plans and Medicare Part D formularies exclude Tadalafil when prescribed for ED. Coverage for BPH is more common but may require prior authorization or step therapy (typically requiring a trial of an alpha-blocker first).
This means most ED patients will pay out-of-pocket. Fortunately, generic pricing is favorable — as low as $9-$45 for 30 tablets with pharmacy discount programs.
From an availability standpoint, the most commonly stocked strengths are 5 mg (daily) and 20 mg (as-needed). The 2.5 mg and 10 mg tablets may be less reliably stocked at some pharmacies. If a patient reports difficulty finding their specific dose, consider whether an alternative strength would be clinically appropriate.
A significant and growing share of Tadalafil prescriptions originate from telehealth platforms (Hims, Ro, BlueChew, etc.). These services typically prescribe generic Tadalafil and ship directly to patients, bypassing traditional pharmacy availability concerns. For patients who face recurring pharmacy stock-outs, telehealth with direct delivery may be a practical recommendation.
The generic Tadalafil market is healthy:
For PAH patients taking Tadalafil (Adcirca/Alyq) at the 40 mg daily dose, availability has also been stable, though specialty pharmacy channels are often used for this indication.
Providers should be prepared to discuss cost with patients, especially those paying out-of-pocket for ED:
Eli Lilly does not currently offer a manufacturer savings card for Cialis. However, the Lilly Cares Foundation provides a patient assistance program for uninsured or underinsured patients based on income eligibility.
For patients who need help navigating costs, the patient-facing resource How to Save Money on Tadalafil may be useful to share.
Several tools can help streamline the process of ensuring patients can fill their Tadalafil prescriptions:
Medfinder offers real-time pharmacy inventory checking that can help your staff or patients identify which nearby pharmacies have Tadalafil in stock. This eliminates the inefficiency of patients calling multiple pharmacies or arriving to find their medication unavailable.
Directing patients to discount coupon platforms (GoodRx, SingleCare, RxSaver, BuzzRx, Optum Perks) can reduce their out-of-pocket cost by 80-95% compared to retail cash prices. These are free to use and accepted at most major pharmacies.
When e-prescribing Tadalafil:
If a patient cannot access Tadalafil, the following PDE5 inhibitors are reasonable alternatives:
For a patient-facing comparison, see: Alternatives to Tadalafil.
The Tadalafil supply outlook for 2026 and beyond remains positive. The robust generic market, growing number of distribution channels (including telehealth and online pharmacies), and competitive pricing all support continued access for patients.
The primary challenges for providers are navigating insurance coverage gaps for ED and helping patients understand their cost-saving options. Proactive counseling about discount programs and pharmacy options can prevent treatment interruptions and improve adherence.
Tadalafil remains widely available and affordable in its generic form. While there is no national shortage, providers play a key role in helping patients navigate insurance exclusions, cost barriers, and occasional local stock-outs. Tools like Medfinder for Providers can help streamline this process.
For additional provider-focused guidance, see our companion article: How to Help Your Patients Find Tadalafil in Stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
